Robert Driscoll
Stock Analyst at Wedbush
(3.32)
# 1,085
Out of 5,182 analysts
170
Total ratings
40.76%
Success rate
4.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Reiterates: Outperform | $147 | $139.48 | +5.39% | 10 | Apr 14, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $52 → $58 | $28.19 | +105.75% | 12 | Apr 14, 2026 | |
| REPL Replimune Group | Downgrades: Neutral | $19 → $2 | $2.50 | -20.00% | 9 | Apr 13, 2026 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $37 → $41 | $25.68 | +59.66% | 8 | Apr 2, 2026 | |
| EIKN Eikon Therapeutics | Reiterates: Underperform | $7 | $9.68 | -27.69% | 2 | Mar 31, 2026 | |
| APRE Aprea Therapeutics | Reiterates: Outperform | $7 | $0.82 | +755.75% | 5 | Mar 31, 2026 | |
| BDTX Black Diamond Therapeutics | Maintains: Outperform | $13 → $14 | $2.60 | +438.46% | 11 | Mar 17, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Outperform | $6 → $11 | $4.18 | +163.16% | 10 | Mar 17, 2026 | |
| FHTX Foghorn Therapeutics | Reiterates: Outperform | $10 | $4.76 | +110.08% | 8 | Mar 12, 2026 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $34 → $36 | $13.43 | +168.06% | 6 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $36 | $8.77 | +310.49% | 12 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $19 | $20.98 | -9.44% | 5 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $11 | $10.51 | +4.66% | 10 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $53 | $34.04 | +55.70% | 10 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $66.27 | +5.63% | 1 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $10.30 | +268.93% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $18.07 | +49.42% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $4.09 | -2.20% | 11 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $6 | $0.72 | +729.88% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $17 | $18.80 | -9.57% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $80 | $8.20 | +875.61% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $14.34 | +416.04% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.96 | +308.16% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.58 | +343.04% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.32 | -7.41% | 4 | May 19, 2020 |
Revolution Medicines
Apr 14, 2026
Reiterates: Outperform
Price Target: $147
Current: $139.48
Upside: +5.39%
IDEAYA Biosciences
Apr 14, 2026
Maintains: Outperform
Price Target: $52 → $58
Current: $28.19
Upside: +105.75%
Replimune Group
Apr 13, 2026
Downgrades: Neutral
Price Target: $19 → $2
Current: $2.50
Upside: -20.00%
Arcus Biosciences
Apr 2, 2026
Maintains: Outperform
Price Target: $37 → $41
Current: $25.68
Upside: +59.66%
Eikon Therapeutics
Mar 31, 2026
Reiterates: Underperform
Price Target: $7
Current: $9.68
Upside: -27.69%
Aprea Therapeutics
Mar 31, 2026
Reiterates: Outperform
Price Target: $7
Current: $0.82
Upside: +755.75%
Black Diamond Therapeutics
Mar 17, 2026
Maintains: Outperform
Price Target: $13 → $14
Current: $2.60
Upside: +438.46%
CytomX Therapeutics
Mar 17, 2026
Maintains: Outperform
Price Target: $6 → $11
Current: $4.18
Upside: +163.16%
Foghorn Therapeutics
Mar 12, 2026
Reiterates: Outperform
Price Target: $10
Current: $4.76
Upside: +110.08%
Cullinan Therapeutics
Mar 11, 2026
Maintains: Outperform
Price Target: $34 → $36
Current: $13.43
Upside: +168.06%
Mar 6, 2026
Maintains: Outperform
Price Target: $38 → $36
Current: $8.77
Upside: +310.49%
Mar 6, 2026
Maintains: Outperform
Price Target: $15 → $19
Current: $20.98
Upside: -9.44%
Feb 25, 2026
Maintains: Neutral
Price Target: $9 → $11
Current: $10.51
Upside: +4.66%
Feb 13, 2026
Maintains: Outperform
Price Target: $37 → $53
Current: $34.04
Upside: +55.70%
Dec 11, 2025
Initiates: Outperform
Price Target: $70
Current: $66.27
Upside: +5.63%
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $10.30
Upside: +268.93%
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $18.07
Upside: +49.42%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $4.09
Upside: -2.20%
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $0.72
Upside: +729.88%
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $18.80
Upside: -9.57%
Sep 20, 2024
Reiterates: Outperform
Price Target: $80
Current: $8.20
Upside: +875.61%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $14.34
Upside: +416.04%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $1.96
Upside: +308.16%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.58
Upside: +343.04%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.32
Upside: -7.41%